SVCM
NBIX icon

Saturn V Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Saturn V Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-58,181
Closed -$7.31M – 22
2025
Q2 		$7.31M Buy
+58,181
New +$6.67M 2.96% 14

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Saturn V Capital Management's NBIX Position: Q3 2025 in Review

Saturn V Capital Management sold out of Neurocrine Biosciences (NBIX) in Q3 2025, closing a stake of 58,181 shares — an estimated $7.31M sold.

Saturn V Capital Management first reported a position in NBIX in Q2 2025 and held it in 1 quarter. The position peaked at $7.31M in Q2 2025. 649 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

  • Saturn V Capital Management reported no remaining Neurocrine Biosciences position as of Q3 2025 after selling out during the quarter.
  • Saturn V Capital Management sold 58,181 Neurocrine Biosciences shares in Q3 2025, an estimated $7.31M.
  • Saturn V Capital Management first reported a position in Neurocrine Biosciences in Q2 2025 and held it in 1 quarter.
  • Saturn V Capital Management's Neurocrine Biosciences position peaked at $7.31M in Q2 2025.
  • 649 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Saturn V Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.